Themis Medicare Limited has informed the Exchange that Record date for the purpose of Dividend is 05-Sep-2025.
THEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 3.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Themis Medicare's board approved its Q1 FY26 (quarter ended June 30, 2025) unaudited financial results, reporting standalone revenue of ₹9,757.77 lakhs, down about 20.7% from ₹12,299.38 lakhs in the same quarter last year. The company swung from a profit of ₹1,871.47 lakhs in Q1 FY25 to a loss of ₹1,537.37 lakhs in Q1 FY26, with loss per share of ₹1.67 versus earnings of ₹2.03 a year ago. The results include an exceptional charge of ₹129.39 lakhs linked to the strike-off of its UK wholly-owned subsidiary, Carpo Medicals Limited. The board also withdrew the previously announced merger scheme with Gujarat Themis Biosyn Limited, appointed Ms. Neha Thakore as an additional non-executive independent director and Mr. Viraj Save as Executive President – Sales & Marketing, and fixed September 5, 2025 as the record date for the final dividend for FY25.
Negative near-term sentiment is likely given the sharp revenue decline and swing to a quarterly loss, though the company has confirmed a dividend and signaled a renewed focus on its core domestic formulations business. Shareholders should watch for whether the Q1 weakness stabilises in the coming quarters.